Citicoline Stroke Study "Citicoline 001"


Phase 3 Results


A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. No drug-related serious adverse events or deaths.